Increase confidence in guiding clinical decisions through early and accurate detection with Illuccix®1,2
Initial staging with Illuccix
Patient history:
- Prostate biopsy
- Gleason score: 9
- PSA level: 22.9 ng/mL
Illuccix imaging detected:
Regional lymph node and bone metastases
View Images
Pelvic LNs
Metastasis
Femur Head
Metastasis
Pelvic LNs
Metastasis
PET positive patient
CT
Fused PET/CT
Images are from an independent case study. On-file with Telix Pharmaceuticals. Additional information may be provided upon request. The case study is representative of a patient’s experience with Illuccix. Image results may vary. The Efficacy and Safety Profile of Illuccix is described in the accompanying Full Prescribing Information.³
Illuccix at initial staging provides critical information for clinical decision making¹𝄒²
In a prospective study of 197 patients evaluated with 68Ga-PSMA-11a at initial staging or re-staging after definitive therapy²:
- 69% of patients were restaged
- 57% of patients had management plan changes
BCR with Illuccix
Patient history:
- PSA level at diagnosis: 33 ng/mL
- PSA level post-XBRT: <0.1 ng/mL
- Positive bone scan with recent PSA level: 5.7 ng/mL
Illuccix imaging detected:
- Recurrent carcinoma in prostate
- Metastases in C7 and left iliac crest
View Images
C7 Vertebral
Body Metastasis
Left Iliac
Metastasis
PET positive patient
CT
Fused PET/CT
Images are from an independent case study. On-file with Telix Pharmaceuticals. Additional information may be provided upon request. The case study is representative of a patient’s experience with Illuccix. Image results may vary. The Efficacy and Safety Profile of Illuccix is described in the accompanying Full Prescribing Information.³
68Ga-PSMA-11a impacts physician treatment decisions for patients with suspected BCR⁴
In a retrospective follow-up of treatment decisions for BCR patients who received 68Ga‑PSMA-11 PET/CT for prostate cancer restaging (N=203)⁴:
- 60% of patients had a change in management
- 45% of patients who had treatment changes had complete responses
BCR with lluccix + uEXPLORER
Patient history:
- Prostate adenocarcinoma with pretreatment PSA levels at 15.67 ng/mL, and a Gleason score of 9
- All treatment modalities (eg, radiation, chemotherapy, ADT, and surgery) were followed by BCR
Illuccix imaging detected:
Diffuse PSMA PET-positive osseous and lymph node metastases and PSMA PET-negative lung metastases
Osseous and LN Metastasis
Fused PET/CT
View Images
Images are from an independent case study from BAMF Health, Grand Rapids, MI. The case study is representative of a patient’s experience with Illuccix and the uEXPLORER. Image results may vary. The Efficacy and Safety Profile of Illuccix is described in the accompanying Full Prescribing Information.5
Illuccix combined with uEXPLORER® PET/CT: the cutting edge of prostate cancer detection1,6,7
The world’s first total body 3D PET scanner6-8
uEXPLORER has high sensitivity and has remarkably reduced the scan time to as low as 30 seconds. This innovative technology, combined with Illuccix, has made it possible to detect metastases as small as 2 mm.
a68Ga-PSMA-11 is also known as gallium Ga 68 gozetotide.
